Vaginal swabs are the specimens of choice when screening for Chlamydia trachomatis and Neisseria gonorrhoeae: results from a multicenter evaluation of the APTIMA assays for both infections.

@article{Schachter2005VaginalSA,
  title={Vaginal swabs are the specimens of choice when screening for Chlamydia trachomatis and Neisseria gonorrhoeae: results from a multicenter evaluation of the APTIMA assays for both infections.},
  author={Julius S Schachter and Max A Chernesky and Dean E Willis and Paul M. Fine and David H. Martin and Deanna Fuller and Jeanne Ann Jordan and William M. Janda and Edward W. Hook},
  journal={Sexually transmitted diseases},
  year={2005},
  volume={32 12},
  pages={725-8}
}
BACKGROUND Vaginal swabs were recently U.S. Food and Drug Administration-cleared for detecting Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (GC) using Gen-Probe Incorporated's APTIMA COMBO2 Assay (AC2). We assessed the APTIMA CT Assay (ACT) for CT, APTIMA GC Assay (AGC) for GC, and AC2 for both organisms using patient- and clinician-collected vaginal swabs. METHOD Women attending family planning, obstetrics and gynecology, or sexually transmitted disease (STD) clinics had first-catch… CONTINUE READING